The effect of liposome encapsulation on the pharmacokinetics of recombinant Secretory Leukocyte Protease Inhibitor (rSLPI) therapy after local delivery to a guinea pig asthma model

Pharmaceutical Research

Volumn 28, Issue 9, 2011, Pages 2233-2245

  Gibbons, Aileen ^a   Padilla Carlin, Danielle ^b   Kelly, Ciara ^a   Hickey, Anthony J ^b   Taggart, Clifford ^c   McElvaney, Noel G ^d   Cryan, Sally Ann ^a  

^a ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^d BEAUMONT HOSPITAL   (Ireland)

Author keywords

Asthma; Guinea pig; Intratracheal instillation; Liposome; Lung; rSLPI

Indexed keywords

AMGEN; CHOLESTEROL; DIOLEOYLPHOSPHATIDYLSERINE; LIPOSOME; RECOMBINANT SECRETORY LEUKOCYTE PROTEASE INHIBITOR; SECRETORY LEUKOCYTE PROTEINASE INHIBITOR; UNCLASSIFIED DRUG;

AIRWAY EPITHELIAL CELL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTHMA; BASOPHIL; CELL INFILTRATION; CELL LEVEL; CONTROLLED STUDY; DISEASE MODEL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE REGIMEN; DRUG INSTILLATION; DRUG PENETRATION; DRUG STABILITY; DRUG TRANSPORT; DRUG UPTAKE; ENCAPSULATION; EOSINOPHIL; EPITHELIUM CELL; GUINEA PIG; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; LIPOSOMAL DELIVERY; LUNG LAVAGE; LYMPHOCYTE; MALE; MONOCYTE; MONOLAYER CULTURE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; RESPIRATORY EPITHELIUM; SINGLE DRUG DOSE;

EID: 80054733915     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-011-0454-1     Document Type: Article

References (59)

1. Barnes PJ. Chronic obstructive pulmonary disease. N Engl J Med. 2000;343:269-80. (Pubitemid 30490396)
2. Barrios VE, Middleton SC, Kashem MA, Havill AM, Toombs CF, Wright CD. Tryptase mediates hyperresponsiveness in isolated guinea pig bronchi. Life Sci. 1998;63:2295-303. (Pubitemid 28557268)
3. Bergenfeldt M, Bjork P, Ohlsson K. The elimination of secretory leukocyte protease inhibitor (SLPI) after intravenous injection in dog and man. Scand J Clin Lab Invest. 1990;50:729-37. (Pubitemid 20369260)
4. Bhavane R, Karathanasis E, Annapragada AV. Agglomerated vesicle technology: a new class of particles for controlled and modulated pulmonary drug delivery. J Control Release. 2003;93:15-28. (Pubitemid 37346265)
5. Brajtburg J, Powderly WG, Kobayashi GS, Medoff G. Amphotericin B: delivery systems. Antimicrob Agents Chemother. 1990;34:381-4. (Pubitemid 20068656)
6. Bratton DL, Henson PM. Apoptotic cell recognition: will the real phosphatidylserine receptor (s) please stand up? Curr Biol. 2008;18:R76-9.
7. Chiu GN, Bally MB, Mayer LD. Selective protein interactions with phosphatidylserine containing liposomes alter the steric stabilization properties of poly (ethylene glycol). Biochim Biophys Acta. 2001;1510:56-69. (Pubitemid 32149885)
8. Conley J, Yang H, Wilson T, Blasetti K, di Ninno V, Schnell G, et al. Aerosol delivery of liposome-encapsulated ciprofloxacin: aerosol characterization and efficacy against Francisella tularensis infection in mice. Antimicrob Agents Chemother. 1997;41:1288-92. (Pubitemid 27231428)
9. Couvreur P, Fattal E, Andremont A. Liposomes and nanoparticles in the treatment of intracellular bacterial infections. Pharm Res. 1991;8:1079-86.
10. Danahay H, Broadley KJ. Effects of inhibitors of phosphodiesterase, on antigen-induced bronchial hyperreactivity in conscious sensitized guinea-pigs and airway leukocyte infiltration. Br J Pharmacol. 1997;120:289-97. (Pubitemid 27039279)
11. de Haan A, Groen G, Prop J, van Rooijen N, Wilschut J. Mucosal immunoadjuvant activity of liposomes: role of alveolar macrophages. Immunology. 1996;89:488-93. (Pubitemid 26419647)
12. Fadok VA, Voelker DR, Campbell PA, Cohen JJ, Bratton DL, Henson PM. Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophages. J Immunol. 1992;148:2207-16.
13. Fahy JV, Kim KW, Liu J, Boushey HA. Prominent neutrophilic inflammation in sputum from subjects with asthma exacerbation. J Allergy Clin Immunol. 1995;95:843-52.
14. Fiegel J, Ehrhardt C, Schaefer UF, Lehr CM, Hanes J. Large porous particle impingement on lung epithelial cell monolayers-toward improved particle characterization in the lung. Pharm Res. 2003;20:788-96. (Pubitemid 36515312)
15. Fogh J, Fogh JM, Orfeo T. One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice. J Natl Cancer Inst. 1977;59:221-6. (Pubitemid 8144854)
16. Forteza RM, Ahmed A, Lee T, Abraham WM. Secretory leukocyte protease inhibitor, but not alpha-1 protease inhibitor, blocks tryptase-induced bronchoconstriction. Pulm Pharmacol Ther. 2001;14:107-10. (Pubitemid 32553614)
17. Foster KA, Yazdanian M, Audus KL. Microparticulate uptake mechanisms of in-vitro cell culture models of the respiratory epithelium. J Pharm Pharmacol. 2001;53:57-66. (Pubitemid 32123700)
18. Frigas E, Gleich GJ. The eosinophil and the pathophysiology of asthma. J Allergy Clin Immunol. 1986;77:527-37. (Pubitemid 16101438)
19. Fryksmark U, Ohlsson K, Polling A, Tegner H. Distribution of antileukoprotease in upper respiratory mucosa. Ann Otol Rhinol Laryngol. 1982;91:268-71. (Pubitemid 12081826)
20. Gast A, Anderson W, Probst A, Nick H, Thompson RC, Eisenberg SP, et al. Pharmacokinetics and distribution of recombinant secretory leukocyte proteinase inhibitor in rats. Am Rev Respir Dis. 1990;141:889-94. (Pubitemid 20157715)
21. Gavalda J, Martin MT, Lopez P, Gomis X, Ramirez JL, Rodriguez D, et al. Efficacy of nebulized liposomal amphotericin B in treatment of experimental pulmonary aspergillosis. Antimicrob Agents Chemother. 2005;49:3028-30. (Pubitemid 40917634)
22. Gavalda J, Martin T, Lopez P, Gomis X, Ramirez JL, Rodriguez D, et al. Efficacy of high loading doses of liposomal amphotericin B in the treatment of experimental invasive pulmonary aspergillosis. Clin Microbiol Infect. 2005;11:999-1004. (Pubitemid 41748934)
23. Gibbons AM, Mcelvaney NG, Taggart CC, Cryan SA. Delivery of rSLPI in a liposomal carrier for inhalation provides protection against cathepsin L degradation. J Microencapsul. 2008:1-10
24. Greene CM, McElvaney NG, O'Neill SJ, Taggart CC. Secretory leucoprotease inhibitor impairs toll-like receptor 2-and 4-mediated responses in monocytic cells. Infect Immun. 2004;72:3684-7. (Pubitemid 38697804)
25. Griffiths GD, Phillips GJ, Bailey SC. Comparison of the quality of protection elicited by toxoid and peptide liposomal vaccine formulations against ricin as assessed by markers of inflammation. Vaccine. 1999;17:2562-8. (Pubitemid 29314449)
26. Janknegt R. Liposomal formulations of cytotoxic drugs. Support Care Cancer. 1996;4:298-304. (Pubitemid 126469652)
27. Janknegt R, de Marie S, Bakker-Woudenberg IA, Crommelin DJ. Liposomal and lipid formulations of amphotericin B. Clinical pharmacokinetics. Clin Pharmacokinet. 1992;23:279-91.
28. Jin FY, Nathan C, Radzioch D, Ding A. Secretory leukocyte protease inhibitor: a macrophage product induced by and antagonistic to bacterial lipopolysaccharide. Cell. 1997;88:417-26. (Pubitemid 27131383)
29. Lentsch AB, Jordan JA, Czermak BJ, Diehl KM, Younkin EM, Sarma V, et al. Inhibition of NF-kappaB activation and augmentation of IkappaBbeta by secretory leukocyte protease inhibitor during lung inflammation. Am J Pathol. 1999;154:239-47. (Pubitemid 29031631)
30. Letsou GV, Safi HJ, Reardon MJ, Ergenoglu M, Li Z, Klonaris CN, et al. Pharmacokinetics of liposomal aerosolized cyclosporine A for pulmonary immunosuppression. Ann Thorac Surg. 1999;68:2044-8. (Pubitemid 30027822)
31. Lopez-Berestein G, Mehta R, Hopfer RL, Mills K, Kasi L, Mehta K, et al. Treatment and prophylaxis of disseminated infection due to Candida albicans in mice with liposome-encapsulated amphotericin B. J Infect Dis. 1983;147:939-45. (Pubitemid 13094246)
32. Martin SJ, Reutelingsperger CP, McGahon AJ, Rader JA, van Schie RC, Laface DM, et al. Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of Bcl-2 and Abl. J Exp Med. 1995;182:1545-56.
33. McCullough HN, Juliano RL. Organ-selective action of an antitumor drug: pharmacologic studies of liposome-encapsulated beta-cytosine arabinoside administered via the respiratory system of the rat. J Natl Cancer Inst. 1979;63:727-31. (Pubitemid 10225000)
34. McElvaney NG, Doujaiji B, Moan MJ, Burnham MR, Wu MC, Crystal RG. Pharmacokinetics of recombinant secretory leukoprotease inhibitor aerosolized to normals and individuals with cystic fibrosis. Am Rev Respir Dis. 1993;148:1056-60. (Pubitemid 23301230)
35. McElvaney NG, Nakamura H, Birrer P, Hebert CA, Wong WL, Alphonso M, et al. Modulation of airway inflammation in cystic fibrosis. In vivo suppression of interleukin-8 levels on the respiratory epithelial surface by aerosolization of recombinant secretory leukoprotease inhibitor. J Clin Invest. 1992;90:1296-301.
36. McNeely TB, Dealy M, Dripps DJ, Orenstein JM, Eisenberg SP, Wahl SM. Secretory leukocyte protease inhibitor: a human saliva protein exhibiting anti-human immunodeficiency virus 1 activity in vitro. J Clin Invest. 1995;96:456-64.
37. Mooren HW, Kramps JA, Franken C, Meijer CJ, Dijkman JA. Localisation of a low-molecular-weight bronchial protease inhibitor in the peripheral human lung. Thorax. 1983;38:180-3. (Pubitemid 13162061)
38. Murata E, Sharmin S, Shiota H, Shiota M, Yano M, Kido H. The effect of topically applied secretory leukocyte protease inhibitor on the eosinophil response in the late phase of allergic conjunctivitis. Curr Eye Res. 2003;26:271-6. (Pubitemid 36876228)
39. Murry DJ, Blaney SM. Clinical pharmacology of encapsulated sustained-release cytarabine. Ann Pharmacother. 2000;34:1173-8.
40. Niven RW, Schreier H. Nebulization of liposomes. I. Effects of lipid composition. Pharm Res. 1990;7:1127-33.
41. O'byrne PM, Postma DS. The many faces of airway inflammation. Asthma and chronic obstructive pulmonary disease. Asthma Research Group. Am J Respir Crit Care Med. 1999;159:S41-63.
42. Sehnert B, Cavcic A, Bohm B, Kalden JR, Nandakumar KS, Holmdahl R, et al. Antileukoproteinase: modulation of neutrophil function and therapeutic effects on anti-type II collagen antibodyinduced arthritis. Arthritis Rheum. 2004;50:2347-59. (Pubitemid 38924415)
43. Shen BQ, Finkbeiner WE, Wine JJ, Mrsny RJ, Widdicombe JH. Calu-3: a human airway epithelial cell line that shows cAMP-dependent Cl-secretion. Am J Physiol. 1994;266:L493-501.
44. Smith N, Broadley KJ. Optimisation of the sensitisation conditions for an ovalbumin challenge model of asthma. Int Immunopharmacol. 2007;7:183-90. (Pubitemid 46037557)
45. Smith N, Johnson FJ. Early-and late-phase bronchoconstriction, airway hyper-reactivity and cell influx into the lungs, after 5'-adenosine monophosphate inhalation: comparison with ovalbumin. Clin Exp Allergy. 2005;35:522-30. (Pubitemid 40577247)
46. Smith RM, Traber LD, Traber DL, Spragg RG. Pulmonary deposition and clearance of aerosolized alpha-1-proteinase inhibitor administered to dogs and to sheep. J Clin Invest. 1989;84:1145-54. (Pubitemid 19247584)
47. Stolk J, Camps J, Feitsma HI, Hermans J, Dijkman JH, Pauwels EK. Pulmonary deposition and disappearance of aerosolised secretory leucocyte protease inhibitor. Thorax. 1995;50:645-50.
48. Taggart CC, Cryan SA, Weldon S, Gibbons A, Greene CM, Kelly E, et al. Secretory leucoprotease inhibitor binds to NF-kappaB binding sites in monocytes and inhibits p65 binding. J Exp Med. 2005;202:1659-68. (Pubitemid 41815872)
49. Taggart CC, Greene CM, McElvaney NG, O'Neill S. Secretory leucoprotease inhibitor prevents lipopolysaccharide-induced IkappaBalpha degradation without affecting phosphorylation or ubiquitination. J Biol Chem. 2002;277:33648-53.
50. Taggart CC, Lowe GJ, Greene CM, Mulgrew AT, O'Neill SJ, Levine RL, et al. Cathepsin B, L, and S cleave and inactivate secretory leucoprotease inhibitor. J Biol Chem. 2001;276:33345-52.
51. Taylor KM, Taylor G, Kellaway IW, Stevens J. The influence of liposomal encapsulation on sodium cromoglycate pharmacokinetics in man. Pharm Res. 1989;6:633-6. (Pubitemid 19214431)
52. Toward TJ, Broadley KJ. Early and late bronchoconstrictions, airway hyper-reactivity, leucocyte influx and lung histamine and nitric oxide after inhaled antigen: effects of dexamethasone and rolipram. Clin Exp Allergy. 2004;34:91-102. (Pubitemid 38183686)
53. Vogelmeier C, Buhl R, Hoyt RF, Wilson E, Fells GA, Hubbard RC, et al. Aerosolization of recombinant SLPI to augment antineutrophil elastase protection of pulmonary epithelium. J Appl Physiol. 1990;69:1843-8.
54. Vogelmeier C, Gillissen A, Buhl R. Use of secretory leukoprotease inhibitor to augment lung antineutrophil elastase activity. Chest. 1996;110:261S-6.
55. Wenzel SE, Fowler 3rd AA, Schwartz LB. Activation of pulmonary mast cells by bronchoalveolar allergen challenge. In vivo release of histamine and tryptase in atopic subjects with and without asthma. Am Rev Respir Dis. 1988;137:1002-8.
56. Wong JP, Yang H, Blasetti KL, Schnell G, Conley J, Schofield LN. Liposome delivery of ciprofloxacin against intracellular Francisella tularensis infection. J Control Release. 2003;92:265-73. (Pubitemid 38366150)
57. Wright CD, Havill AM, Middleton SC, Kashem MA, Lee PA, Dripps DJ, et al. Secretory leukocyte protease inhibitor prevents allergen-induced pulmonary responses in animal models of asthma. J Pharmacol Exp Ther. 1999;289:1007-14. (Pubitemid 29191260)
58. Yang J, Zhu J, Sun D, Ding A. Suppression of macrophage responses to bacterial lipopolysaccharide (LPS) by secretory leukocyte protease inhibitor (SLPI) is independent of its antiprotease function. Biochim Biophys Acta. 2005;1745:310-7. (Pubitemid 41330785)
59. Zhang Y, Dewitt DL, McNeely TB, Wahl SM, Wahl LM. Secretory leukocyte protease inhibitor suppresses the production of monocyte prostaglandin H synthase-2, prostaglandin E2, and matrix metalloproteinases. J Clin Invest. 1997;99:894-900. (Pubitemid 27123626)